Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
13.35 SEK | -1.11% |
|
-1.48% | +78.00% |
07-02 | IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee | CI |
05-27 | Sweden’s IRLAB Therapeutics Names New CEO | MT |